209 related articles for article (PubMed ID: 33817720)
1. Osteopontin and osteoprotegerin in atherosclerotic plaque - are they significant markers of plaque vulnerability?
Strobescu-Ciobanu C; Giuşcă SE; Căruntu ID; Amălinei C; Rusu A; Cojocaru E; Popa RF; Lupaşcu CD
Rom J Morphol Embryol; 2020; 61(3):793-801. PubMed ID: 33817720
[TBL] [Abstract][Full Text] [Related]
2. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability.
Kadoglou NP; Gerasimidis T; Golemati S; Kapelouzou A; Karayannacos PE; Liapis CD
J Vasc Surg; 2008 Jan; 47(1):55-62. PubMed ID: 18178454
[TBL] [Abstract][Full Text] [Related]
3. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Liapis CD
J Vasc Surg; 2010 Jan; 51(1):114-21. PubMed ID: 19837545
[TBL] [Abstract][Full Text] [Related]
4. Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma.
Higgins CL; Isbilir S; Basto P; Chen IY; Vaduganathan M; Vaduganathan P; Reardon MJ; Lawrie G; Peterson L; Morrisett JD
Protein J; 2015 Oct; 34(5):315-28. PubMed ID: 26307009
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability.
Straface G; Biscetti F; Pitocco D; Bertoletti G; Misuraca M; Vincenzoni C; Snider F; Arena V; Stigliano E; Angelini F; Iuliano L; Boccia S; de Waure C; Giacchi F; Ghirlanda G; Flex A
Stroke; 2011 Nov; 42(11):3022-8. PubMed ID: 21903966
[TBL] [Abstract][Full Text] [Related]
6. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
[TBL] [Abstract][Full Text] [Related]
7. N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients.
Wolak T; Sion-Vardi N; Novack V; Greenberg G; Szendro G; Tarnovscki T; Nov O; Shelef I; Paran E; Rudich A
Am J Hypertens; 2013 Mar; 26(3):326-33. PubMed ID: 23382482
[TBL] [Abstract][Full Text] [Related]
8. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
[TBL] [Abstract][Full Text] [Related]
9. The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods.
Basiak M; Hachula M; Kosowski M; Machnik G; Maliglowka M; Dziubinska-Basiak M; Krysiak R; Okopien B
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570897
[TBL] [Abstract][Full Text] [Related]
10. Plasma Concentrations of New Biochemical Markers of Atherosclerosis in Patients with Dyslipidemia-A Pilot Study.
Kosowski M; Basiak M; Hachuła M; Okopień B
Medicina (Kaunas); 2022 May; 58(6):. PubMed ID: 35743980
[TBL] [Abstract][Full Text] [Related]
11. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis.
Kadoglou NP; Gerasimidis T; Moumtzouoglou A; Kapelouzou A; Sailer N; Fotiadis G; Vitta I; Katinios A; Kougias P; Bandios S; Voliotis K; Karayannacos PE; Liapis CD
Eur J Vasc Endovasc Surg; 2008 Jun; 35(6):661-8. PubMed ID: 18395477
[TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans.
Vik A; Mathiesen EB; Notø AT; Sveinbjørnsson B; Brox J; Hansen JB
Atherosclerosis; 2007 Mar; 191(1):128-34. PubMed ID: 16620835
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.
Tousoulis D; Siasos G; Maniatis K; Oikonomou E; Kioufis S; Zaromitidou M; Paraskevopoulos T; Michalea S; Kollia C; Miliou A; Kokkou E; Papavassiliou AG; Stefanadis C
Int J Cardiol; 2013 Sep; 167(5):1924-8. PubMed ID: 22640692
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of osteopontin, and osteoprotegerin mRNA in epicardial adipose tissue between patients with severe coronary artery disease and aortic valvular stenosis: association with HDL subclasses.
Luna-Luna M; Cruz-Robles D; Ávila-Vanzzini N; Herrera-Alarcón V; Martínez-Reding J; Criales-Vera S; Sandoval-Zárate J; Vargas-Barrón J; Martínez-Sánchez C; Tovar-Palacio AR; Fragoso JM; Carreón-Torres E; Vargas-Alarcón G; Pérez-Méndez Ó
Lipids Health Dis; 2017 Aug; 16(1):156. PubMed ID: 28821297
[TBL] [Abstract][Full Text] [Related]
15. Expression of NPP1 is regulated during atheromatous plaque calcification.
Nitschke Y; Hartmann S; Torsello G; Horstmann R; Seifarth H; Weissen-Plenz G; Rutsch F
J Cell Mol Med; 2011 Feb; 15(2):220-31. PubMed ID: 20015201
[TBL] [Abstract][Full Text] [Related]
16. Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease.
Kadoglou NPE; Kapetanios D; Korakas E; Valsami G; Tentolouris N; Papanas N; Lambadiari V; Karkos C
Cardiovasc Diabetol; 2022 Sep; 21(1):171. PubMed ID: 36050687
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability.
Davaine JM; Quillard T; Brion R; Lapérine O; Guyomarch B; Merlini T; Chatelais M; Guilbaud F; Brennan MÁ; Charrier C; Heymann D; Gouëffic Y; Heymann MF
PLoS One; 2014; 9(9):e107642. PubMed ID: 25259713
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of osteopontin and osteoprotegerin levels in abdominal aortic aneurysm patients].
Czyzewska-Buczyńska A; Zuk N; Bałasz S; Witkiewicz W
Przegl Lek; 2013; 70(3):102-5. PubMed ID: 24003660
[TBL] [Abstract][Full Text] [Related]
19. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
Barchetta I; Ceccarelli V; Cimini FA; Bertoccini L; Fraioli A; Alessandri C; Lenzi A; Baroni MG; Cavallo MG
J Endocrinol Invest; 2019 May; 42(5):513-520. PubMed ID: 30132286
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis.
Golledge J; McCann M; Mangan S; Lam A; Karan M
Stroke; 2004 Jul; 35(7):1636-41. PubMed ID: 15143295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
